RU2012140185A - Ингибирование ангиогенеза - Google Patents
Ингибирование ангиогенеза Download PDFInfo
- Publication number
- RU2012140185A RU2012140185A RU2012140185/15A RU2012140185A RU2012140185A RU 2012140185 A RU2012140185 A RU 2012140185A RU 2012140185/15 A RU2012140185/15 A RU 2012140185/15A RU 2012140185 A RU2012140185 A RU 2012140185A RU 2012140185 A RU2012140185 A RU 2012140185A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- tumor
- csf
- antitumor agent
- additional antitumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
Abstract
1. Способ лечения опухоли, который включает введение субъекту-человеку, несущему опухоль, эффективного количества антагониста G-CSF.2. Способ по п.1, где антагонист G-CSF представляет собой антитело против G-CSF.3. Способ по п.2, который дополнительно включает введение дополнительного противоопухолевого средства.4. Способ по п.3, где дополнительным противоопухолевым средством является антитело против Bv8 и/или антитело против VEGF.
Claims (4)
1. Способ лечения опухоли, который включает введение субъекту-человеку, несущему опухоль, эффективного количества антагониста G-CSF.
2. Способ по п.1, где антагонист G-CSF представляет собой антитело против G-CSF.
3. Способ по п.2, который дополнительно включает введение дополнительного противоопухолевого средства.
4. Способ по п.3, где дополнительным противоопухолевым средством является антитело против Bv8 и/или антитело против VEGF.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97438207P | 2007-09-21 | 2007-09-21 | |
| US60/974,382 | 2007-09-21 | ||
| US8307108P | 2008-07-23 | 2008-07-23 | |
| US61/083,071 | 2008-07-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010115755/15A Division RU2471498C2 (ru) | 2007-09-21 | 2008-09-19 | Ингибирование ангиогенеза |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012140185A true RU2012140185A (ru) | 2014-03-27 |
Family
ID=40030248
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010115755/15A RU2471498C2 (ru) | 2007-09-21 | 2008-09-19 | Ингибирование ангиогенеза |
| RU2012140185/15A RU2012140185A (ru) | 2007-09-21 | 2012-09-19 | Ингибирование ангиогенеза |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010115755/15A RU2471498C2 (ru) | 2007-09-21 | 2008-09-19 | Ингибирование ангиогенеза |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9284369B2 (ru) |
| EP (1) | EP2203479B1 (ru) |
| JP (1) | JP5615709B2 (ru) |
| KR (1) | KR101578945B1 (ru) |
| CN (1) | CN102037015B (ru) |
| AR (1) | AR068532A1 (ru) |
| AU (1) | AU2008302214B2 (ru) |
| CA (1) | CA2700276A1 (ru) |
| CL (1) | CL2008002782A1 (ru) |
| CO (1) | CO6270370A2 (ru) |
| ES (1) | ES2568881T3 (ru) |
| IL (1) | IL204502A (ru) |
| MX (1) | MX2010003013A (ru) |
| NZ (1) | NZ584787A (ru) |
| PE (1) | PE20091197A1 (ru) |
| RU (2) | RU2471498C2 (ru) |
| TW (1) | TWI457349B (ru) |
| WO (1) | WO2009039337A2 (ru) |
| ZA (1) | ZA201001868B (ru) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0212070A (pt) * | 2001-08-29 | 2004-09-28 | Genentech Inc | ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica |
| AU2004219592C1 (en) | 2003-03-12 | 2011-02-24 | Genentech, Inc. | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| WO2008109377A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
| KR20120089253A (ko) * | 2009-07-31 | 2012-08-09 | 제넨테크, 인크. | Ｂｖ８? 또는 ｇ?ｃｓｆ?길항제를 이용한 종양 전이의 억제 |
| PT2488554T (pt) | 2009-10-14 | 2019-09-13 | Humanigen Inc | Anticorpos para epha3 |
| NZ600826A (en) * | 2009-12-23 | 2014-09-26 | Genentech Inc | Anti-bv8 antibodies and uses thereof |
| US9375473B2 (en) | 2010-02-19 | 2016-06-28 | Cornell Research Foundation, Inc. | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
| CA2838246C (en) | 2011-06-13 | 2018-07-10 | Csl Limited | Antibodies against g-csfr and uses thereof |
| MX2014001736A (es) * | 2011-08-17 | 2014-03-31 | Genentech Inc | Inhibicion de angiogenesis en tumores refractarios. |
| WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
| US20150118215A1 (en) * | 2012-03-30 | 2015-04-30 | The General Hospital Corporation | Methods of Inhibiting Cell Proliferation |
| TWI498425B (zh) * | 2013-01-08 | 2015-09-01 | Nat Univ Tsing Hua | 層析濾紙型酵素連結免疫吸附分析法 |
| EP2968557A4 (en) * | 2013-03-13 | 2016-09-28 | Health Research Inc | IMPROVING VACCINES |
| KR102494803B1 (ko) * | 2013-11-22 | 2023-02-06 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| CN104237223B (zh) * | 2014-10-08 | 2017-04-12 | 江苏奥赛康药业股份有限公司 | 测定铁‑碳水化合物络合物中不稳定铁含量的方法 |
| CN104587469A (zh) * | 2015-01-19 | 2015-05-06 | 马洁 | G-csf拮抗剂在治疗慢性炎症、预防炎症相关肿瘤中的应用 |
| WO2017096124A1 (en) * | 2015-12-03 | 2017-06-08 | National Health Research Institutes | Heterodimeric vascular endothelial growth factor and use thereof |
| WO2018108862A1 (en) * | 2016-12-12 | 2018-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of prokineticin receptor 2 for use as a medicament for treating an eg-vegf-related cancer |
| JP7465210B2 (ja) * | 2017-11-29 | 2024-04-10 | シーエスエル リミティド | 虚血－再灌流障害の治療又は予防方法 |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| US12281160B2 (en) | 2018-03-23 | 2025-04-22 | Csl Limited | Method of treating asthma |
| MA54325A (fr) | 2019-06-05 | 2022-05-11 | Regeneron Pharma | Dispositifs et procédés pour l'administration précise de doses |
| AU2020393842A1 (en) | 2019-11-25 | 2022-06-16 | The Regents Of The University Of California | Long-acting VEGF inhibitors for intraocular neovascularization |
| CN115768475A (zh) | 2020-06-04 | 2023-03-07 | Csl创新私人有限公司 | 治疗或预防急性呼吸窘迫综合征的方法 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| AU2024290964A1 (en) | 2023-07-05 | 2026-01-08 | CSL Innovation Pty Ltd | Methods of treating or preventing a complication of sickle cell disease |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| BR0212070A (pt) * | 2001-08-29 | 2004-09-28 | Genentech Inc | ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CN1802169A (zh) * | 2003-03-12 | 2006-07-12 | 健泰科生物技术公司 | Bv8和/或EG－VEGF促进造血的用途 |
| AU2004219592C1 (en) * | 2003-03-12 | 2011-02-24 | Genentech, Inc. | Use of Bv8 and/or EG-VEGF to promote hematopoiesis |
| NZ621449A (en) | 2003-05-30 | 2015-07-31 | Genentech Inc | Treatment with anti-vegf antibodies |
| EP1924603A2 (en) * | 2005-09-13 | 2008-05-28 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
| ITRM20070182A1 (it) | 2007-04-03 | 2008-10-04 | Univ Roma | Antagonisti dei recettori delle prochineticine derivati di essi e loro uso |
-
2008
- 2008-09-17 CL CL2008002782A patent/CL2008002782A1/es unknown
- 2008-09-19 EP EP08832515.4A patent/EP2203479B1/en active Active
- 2008-09-19 CA CA2700276A patent/CA2700276A1/en not_active Abandoned
- 2008-09-19 WO PCT/US2008/076954 patent/WO2009039337A2/en not_active Ceased
- 2008-09-19 KR KR1020107008635A patent/KR101578945B1/ko not_active Expired - Fee Related
- 2008-09-19 PE PE2008001642A patent/PE20091197A1/es not_active Application Discontinuation
- 2008-09-19 AU AU2008302214A patent/AU2008302214B2/en not_active Ceased
- 2008-09-19 NZ NZ584787A patent/NZ584787A/xx not_active IP Right Cessation
- 2008-09-19 JP JP2010525989A patent/JP5615709B2/ja not_active Expired - Fee Related
- 2008-09-19 RU RU2010115755/15A patent/RU2471498C2/ru not_active IP Right Cessation
- 2008-09-19 US US12/679,257 patent/US9284369B2/en not_active Expired - Fee Related
- 2008-09-19 TW TW097136179A patent/TWI457349B/zh not_active IP Right Cessation
- 2008-09-19 MX MX2010003013A patent/MX2010003013A/es active IP Right Grant
- 2008-09-19 ES ES08832515.4T patent/ES2568881T3/es active Active
- 2008-09-19 CN CN200880117292.XA patent/CN102037015B/zh not_active Expired - Fee Related
- 2008-09-22 AR ARP080104117A patent/AR068532A1/es unknown
-
2010
- 2010-03-15 IL IL204502A patent/IL204502A/en not_active IP Right Cessation
- 2010-03-16 ZA ZA2010/01868A patent/ZA201001868B/en unknown
- 2010-04-14 CO CO10043417A patent/CO6270370A2/es not_active Application Discontinuation
-
2012
- 2012-09-19 RU RU2012140185/15A patent/RU2012140185A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US9284369B2 (en) | 2016-03-15 |
| IL204502A (en) | 2015-05-31 |
| WO2009039337A3 (en) | 2009-05-14 |
| AU2008302214B2 (en) | 2012-10-25 |
| KR101578945B1 (ko) | 2015-12-21 |
| RU2471498C2 (ru) | 2013-01-10 |
| AR068532A1 (es) | 2009-11-18 |
| EP2203479A2 (en) | 2010-07-07 |
| ZA201001868B (en) | 2011-06-29 |
| PE20091197A1 (es) | 2009-08-14 |
| ES2568881T3 (es) | 2016-05-05 |
| TWI457349B (zh) | 2014-10-21 |
| MX2010003013A (es) | 2010-08-02 |
| NZ584787A (en) | 2012-12-21 |
| TW200920750A (en) | 2009-05-16 |
| AU2008302214A1 (en) | 2009-03-26 |
| CN102037015B (zh) | 2016-02-03 |
| CL2008002782A1 (es) | 2009-07-31 |
| CA2700276A1 (en) | 2009-03-26 |
| JP5615709B2 (ja) | 2014-10-29 |
| EP2203479B1 (en) | 2016-01-27 |
| HK1141538A1 (zh) | 2010-11-12 |
| WO2009039337A2 (en) | 2009-03-26 |
| US20100316633A1 (en) | 2010-12-16 |
| KR20100075513A (ko) | 2010-07-02 |
| CN102037015A (zh) | 2011-04-27 |
| JP2010540449A (ja) | 2010-12-24 |
| RU2010115755A (ru) | 2011-10-27 |
| CO6270370A2 (es) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
| EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| EA201071038A1 (ru) | Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
| EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
| EA201071268A1 (ru) | СПОСОБ ЛЕЧЕНИЯ РАКА С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА cMET И AXL И ИНГИБИТОРА erbB | |
| EA201791669A2 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
| EA201390682A1 (ru) | Спирооксиндольные антагонисты mdm2 | |
| UA113403C2 (xx) | Спосіб підвищення ефективності folr1 терапії раку | |
| UA107814C2 (ru) | Спирооксиндольные антагонисты mdm 2 | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| EA201270247A1 (ru) | Способы применения с-мет-модуляторов | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| EA201591825A1 (ru) | Антагонизм миостатина у субъектов - людей | |
| MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| EA201270205A1 (ru) | Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20151120 |